Importantly, the use of a YAP inhibitor can suppress the growth of uveal melanoma cells both in vitro and in vivo, which strongly supports the notion of targeting YAP to treat uveal melanomas with Gαq and Gα11 mutations [108,109]. The gene discussed is GNAQ; the disease is uveal melanoma.